Healthcare Economist Unbiased Analysis of Today’s Healthcare Issues
- Are you fluent in AI?by Jason Shafrin on May 28, 2026 at 12:02 am
Professor Rick Dakan (Ringling College of Art and Design) and Professor Joseph Feller (University College Cork) developed the 4D Framework for AI Fluency. What is it? Delegation: Deciding on what work should be done by humans, what work should be done by AI, and how to distribute tasks between them. Includes understanding your goals, AI capabilities,…
- Are Veterans benefits about to become more generous?by Jason Shafrin on May 27, 2026 at 5:25 am
Perhaps, if the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act becomes law. The bill just recently passed the House of Representatives. Newsweek summarizes the bill’s provisions as follows: The bill would increase Dependency and Indemnity Compensation benefits by 1.5 percent over two years. Those payments are provided by the Department of Veterans Affairs (VA) to…
- Linksby Jason Shafrin on May 22, 2026 at 5:11 am
Ebola outbreak in the Congo. AI Mathematicians. Why Long-Term Care Policy Keeps Failing. ISPOR: first, second and third plenary. The Indiana Bears?
- How long do Europeans have to wait for new pharmaceuticals after EMA approval?by Jason Shafrin on May 21, 2026 at 12:02 am
The answer is provided by EFPIA’s annual WAIT indicator (press release, report). First, we see a large decrease in the share of pharmaceuticals fully availbity, drive by a small increase in reduced availability but a much larger increase in the number of drugs that only have a limited availability. Specifically, Historically full availability was the…
- Medicare Drug Price Negotiation is here to stayby Jason Shafrin on May 19, 2026 at 12:53 pm
At least, it won’t be overturned by the US Supreme Court. Endpoints reports: The Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Novartis and Boehringer Ingelheim… The…